DE19612966B4 - MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren - Google Patents
MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren Download PDFInfo
- Publication number
- DE19612966B4 DE19612966B4 DE19612966A DE19612966A DE19612966B4 DE 19612966 B4 DE19612966 B4 DE 19612966B4 DE 19612966 A DE19612966 A DE 19612966A DE 19612966 A DE19612966 A DE 19612966A DE 19612966 B4 DE19612966 B4 DE 19612966B4
- Authority
- DE
- Germany
- Prior art keywords
- cells
- infection
- influenza viruses
- cell
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000712461 unidentified influenza virus Species 0.000 title claims abstract description 70
- 238000000034 method Methods 0.000 title claims abstract description 60
- 230000001902 propagating effect Effects 0.000 title claims description 6
- 238000004113 cell culture Methods 0.000 claims abstract description 53
- 229960005486 vaccine Drugs 0.000 claims abstract description 36
- 239000000725 suspension Substances 0.000 claims abstract description 19
- 239000012679 serum free medium Substances 0.000 claims abstract description 10
- 230000012010 growth Effects 0.000 claims abstract description 9
- 230000008569 process Effects 0.000 claims abstract description 6
- 208000015181 infectious disease Diseases 0.000 claims description 60
- 241000700605 Viruses Species 0.000 claims description 59
- 230000010412 perfusion Effects 0.000 claims description 25
- 102000004142 Trypsin Human genes 0.000 claims description 23
- 108090000631 Trypsin Proteins 0.000 claims description 23
- 239000012588 trypsin Substances 0.000 claims description 22
- 230000000644 propagated effect Effects 0.000 claims description 13
- 108091005804 Peptidases Proteins 0.000 claims description 12
- 239000004365 Protease Substances 0.000 claims description 12
- 101710154606 Hemagglutinin Proteins 0.000 claims description 8
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 8
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 8
- 101710176177 Protein A56 Proteins 0.000 claims description 8
- 239000001963 growth medium Substances 0.000 claims description 8
- 238000003306 harvesting Methods 0.000 claims description 8
- 239000000185 hemagglutinin Substances 0.000 claims description 7
- 238000010923 batch production Methods 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 102000012479 Serine Proteases Human genes 0.000 claims description 3
- 108010022999 Serine Proteases Proteins 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 230000002238 attenuated effect Effects 0.000 claims description 3
- 239000002243 precursor Substances 0.000 claims description 3
- 210000000605 viral structure Anatomy 0.000 claims description 3
- 239000006285 cell suspension Substances 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 230000002458 infectious effect Effects 0.000 claims 1
- 108700010900 influenza virus proteins Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 154
- 210000004102 animal cell Anatomy 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 239000002609 medium Substances 0.000 description 38
- 239000000427 antigen Substances 0.000 description 20
- 102000036639 antigens Human genes 0.000 description 20
- 108091007433 antigens Proteins 0.000 description 20
- 235000013601 eggs Nutrition 0.000 description 14
- 102000035195 Peptidases Human genes 0.000 description 10
- 241000287828 Gallus gallus Species 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 230000029812 viral genome replication Effects 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 230000003472 neutralizing effect Effects 0.000 description 6
- 238000001914 filtration Methods 0.000 description 5
- 206010022000 influenza Diseases 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 208000037797 influenza A Diseases 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000012770 revaccination Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000004017 serum-free culture medium Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- ZGNLFUXWZJGETL-YUSKDDKASA-N (Z)-[(2S)-2-amino-2-carboxyethyl]-hydroxyimino-oxidoazanium Chemical compound N[C@@H](C\[N+]([O-])=N\O)C(O)=O ZGNLFUXWZJGETL-YUSKDDKASA-N 0.000 description 2
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- MLFKVJCWGUZWNV-UHFFFAOYSA-N L-alanosine Natural products OC(=O)C(N)CN(O)N=O MLFKVJCWGUZWNV-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 208000007696 Multicystic Dysplastic Kidney Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000845082 Panama Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 229950005033 alanosine Drugs 0.000 description 2
- 229960003896 aminopterin Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000009295 crossflow filtration Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001955 cumulated effect Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940082150 encore Drugs 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- -1 lipoid fractions Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000013630 prepared media Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000856 sucrose gradient centrifugation Methods 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (22)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19612966A DE19612966B4 (de) | 1996-04-01 | 1996-04-01 | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| US09/155,581 US6455298B1 (en) | 1996-04-01 | 1997-04-01 | Animal cells and processes for the replication of influenza viruses |
| EP97915627A EP0904351B1 (en) | 1996-04-01 | 1997-04-01 | Animal cells and processes for the replication of influenza viruses |
| EP10075278A EP2275535A1 (en) | 1996-04-01 | 1997-04-01 | Animal cells and processes for the replication of influenza viruses |
| PT97915627T PT904351E (pt) | 1996-04-01 | 1997-04-01 | Células animais e processos para a replicação de vírus influenza |
| PCT/IB1997/000403 WO1997037000A1 (en) | 1996-04-01 | 1997-04-01 | Animal cells and processes for the replication of influenza viruses |
| AT97915627T ATE482267T1 (de) | 1996-04-01 | 1997-04-01 | Tierzellen und verfahren für die replikation von influenza viren |
| JP53508997A JP4243349B2 (ja) | 1996-04-01 | 1997-04-01 | インフルエンザウイルスの複製のための動物細胞および方法 |
| DK97915627.0T DK0904351T3 (da) | 1996-04-01 | 1997-04-01 | Dyreceller og fremgangsmåder til replikationen af influenzavirus |
| CA002250714A CA2250714C (en) | 1996-04-01 | 1997-04-01 | Animal cells and processes for the replication of influenza viruses |
| ES97915627T ES2352638T3 (es) | 1996-04-01 | 1997-04-01 | Células animales y procedimientos de replicación del virus de la gripe. |
| DE69740002T DE69740002D1 (de) | 1996-04-01 | 1997-04-01 | Tierzellen und verfahren für die replikation von influenza viren |
| HK99104226.0A HK1019233B (en) | 1996-04-01 | 1997-04-01 | Animal cells and processes for the replication of influenza viruses |
| US10/194,784 US6656720B2 (en) | 1996-04-01 | 2002-07-12 | Animal cells and processes for the replication of influenza viruses |
| JP2004233905A JP2004331673A (ja) | 1996-04-01 | 2004-08-10 | インフルエンザウイルスの複製のための動物細胞および方法 |
| US11/057,370 US20050202553A1 (en) | 1996-04-01 | 2005-02-15 | Animal cells and processes for the replication of influenza viruses |
| JP2005108075A JP2005211080A (ja) | 1996-04-01 | 2005-04-04 | インフルエンザウイルスの複製のための動物細胞および方法 |
| JP2006147486A JP2006230415A (ja) | 1996-04-01 | 2006-05-26 | インフルエンザウイルスの複製のための動物細胞および方法 |
| US12/146,689 US20080274141A1 (en) | 1996-04-01 | 2008-06-26 | Animal cells and processes for the replication of influenza viruses |
| JP2008287206A JP2009034115A (ja) | 1996-04-01 | 2008-11-07 | インフルエンザウイルスの複製のための動物細胞および方法 |
| JP2011192118A JP2012005502A (ja) | 1996-04-01 | 2011-09-02 | インフルエンザウイルスの複製のための動物細胞および方法 |
| JP2011224914A JP2012016358A (ja) | 1996-04-01 | 2011-10-12 | インフルエンザウイルスの複製のための動物細胞および方法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19655438 | 1996-04-01 | ||
| DE19612966A DE19612966B4 (de) | 1996-04-01 | 1996-04-01 | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE19612966A1 DE19612966A1 (de) | 1997-10-02 |
| DE19612966B4 true DE19612966B4 (de) | 2009-12-10 |
Family
ID=7790126
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19612966A Expired - Fee Related DE19612966B4 (de) | 1996-04-01 | 1996-04-01 | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| DE69740002T Expired - Lifetime DE69740002D1 (de) | 1996-04-01 | 1997-04-01 | Tierzellen und verfahren für die replikation von influenza viren |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69740002T Expired - Lifetime DE69740002D1 (de) | 1996-04-01 | 1997-04-01 | Tierzellen und verfahren für die replikation von influenza viren |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US6455298B1 (enExample) |
| EP (2) | EP0904351B1 (enExample) |
| JP (7) | JP4243349B2 (enExample) |
| AT (1) | ATE482267T1 (enExample) |
| DE (2) | DE19612966B4 (enExample) |
| DK (1) | DK0904351T3 (enExample) |
| ES (1) | ES2352638T3 (enExample) |
| PT (1) | PT904351E (enExample) |
| WO (1) | WO1997037000A1 (enExample) |
Families Citing this family (138)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19612966B4 (de) * | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| DE19612967A1 (de) * | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
| TR200001125T2 (tr) | 1997-10-25 | 2000-09-21 | Roche Diagnostics Gmbh | Retro virüs vektörleri için sübye paketleme hücre sıraları. |
| ATE507284T1 (de) | 1997-12-24 | 2011-05-15 | Abbott Biologicals Bv | Vorbereitung von zellen für die herstellung von biologika |
| JP4698112B2 (ja) * | 2000-03-03 | 2011-06-08 | 一般財団法人化学及血清療法研究所 | 無血清培養かつ浮遊培養可能な細胞及び当該細胞を用いたワクチン用ウイルスの製造法 |
| JP3547715B2 (ja) * | 2001-03-06 | 2004-07-28 | 榮 新垣 | ベクター精製用装置及び方法 |
| DE10144903A1 (de) * | 2001-09-12 | 2003-03-27 | Chiron Behring Gmbh & Co | Vermehrung von Viren in Zellkultur |
| DE10144906B4 (de) * | 2001-09-12 | 2013-11-28 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur großtechnischen Herstellung von Impfstoffen |
| US20030078471A1 (en) * | 2001-10-18 | 2003-04-24 | Foley Frederick J. | Manipulation of an organ |
| US6951752B2 (en) * | 2001-12-10 | 2005-10-04 | Bexter Healthcare S.A. | Method for large scale production of virus antigen |
| AU2003231083A1 (en) * | 2002-04-26 | 2003-11-10 | Medimmune, Llc | Multi plasmid system for the production of influenza virus |
| US20050158342A1 (en) | 2003-12-23 | 2005-07-21 | Medimmune, Inc. | Multi plasmid system for the production of influenza virus |
| US7465456B2 (en) * | 2002-04-26 | 2008-12-16 | Medimmune, Llc | Multi plasmid system for the production of influenza virus |
| US20060110406A1 (en) * | 2003-02-25 | 2006-05-25 | Medimmune Vaccines, Inc. | Refrigerator-temperature stable influenza vaccine compositions |
| CA2807534A1 (en) | 2003-02-25 | 2005-02-17 | Medimmune Vaccines, Inc. | Methods of producing influenza vaccine compositions |
| MXPA05005306A (es) * | 2003-06-20 | 2005-10-26 | Microbix Biosystems Inc | Mejoramientos en la produccion de virus. |
| WO2005026333A1 (ja) * | 2003-09-09 | 2005-03-24 | Japan Science And Technology Agency | プロテアーゼを用いた接着性細胞の浮遊培養技術、及び該細胞を宿主として用いてウィルスを生産する方法 |
| EP1722815A1 (en) | 2004-03-09 | 2006-11-22 | Chiron Corporation | Influenza virus vaccines |
| BRPI0509493A (pt) * | 2004-04-01 | 2007-09-11 | Alza Corp | aparelho e método para a liberação transdérmica de vacina da influenza |
| NZ551640A (en) * | 2004-05-20 | 2010-05-28 | Id Biomedical Corp | Process for the production of an influenza vaccine |
| JP2008512443A (ja) | 2004-09-09 | 2008-04-24 | カイロン ベーリング ゲーエムベーハー アンド カンパニー | インフルエンザワクチンに関連する潜在的医原性リスクの減少 |
| CA2583698C (en) | 2004-10-06 | 2014-12-02 | Medimmune Vaccines, Inc. | Refrigerator-temperature stable influenza vaccine compositions |
| DE102004049290A1 (de) * | 2004-10-09 | 2006-04-20 | Bayer Healthcare Ag | Verfahren zur Herstellung von Virusmaterial |
| EP2923711A1 (en) | 2004-11-03 | 2015-09-30 | Novartis Vaccines and Diagnostics, Inc. | Influenza vaccination |
| CN102978169A (zh) | 2004-12-08 | 2013-03-20 | 米迪缪尼有限公司 | 生产流感疫苗组合物的方法 |
| EP1831353B1 (en) * | 2004-12-23 | 2012-02-29 | MedImmune, LLC | Non-tumorigenic mdck cell line for propagating viruses |
| US7572620B2 (en) | 2005-01-11 | 2009-08-11 | Wisconsin Alumni Research Foundation | H3 equine influenza A virus |
| FR2884255B1 (fr) | 2005-04-11 | 2010-11-05 | Vivalis | Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe |
| US20070111309A1 (en) * | 2005-10-04 | 2007-05-17 | Daelli Marcelo G | Vero cell line adapted to grow in suspension |
| NZ567817A (en) | 2005-11-01 | 2012-01-12 | Novartis Vaccines & Diagnostic | Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment |
| NZ568210A (en) | 2005-11-04 | 2012-12-21 | Novartis Vaccines & Diagnostic | Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines |
| EP1951302A2 (en) | 2005-11-04 | 2008-08-06 | Novartis Vaccines and Diagnostics S.r.l. | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
| EP1945252B1 (en) | 2005-11-04 | 2013-05-29 | Novartis Vaccines and Diagnostics S.r.l. | Vaccines comprising purified surface antigens prepared from influenza viruses grown in cell culture, adjuvanted with squalene |
| NZ568211A (en) | 2005-11-04 | 2011-11-25 | Novartis Vaccines & Diagnostic | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| CN102755645A (zh) | 2005-11-04 | 2012-10-31 | 诺华疫苗和诊断有限公司 | 佐剂配制的包含细胞因子诱导剂的流感疫苗 |
| JP6087041B2 (ja) * | 2006-01-27 | 2017-03-08 | ノバルティス アーゲー | 血球凝集素およびマトリックスタンパク質を含むインフルエンザウイルスワクチン |
| US20100068223A1 (en) * | 2006-03-24 | 2010-03-18 | Hanno Scheffczik | Storage of Influenza Vaccines Without Refrigeration |
| AU2007245192B2 (en) | 2006-03-31 | 2012-04-12 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
| JP5322636B2 (ja) | 2006-05-11 | 2013-10-23 | 一般財団法人化学及血清療法研究所 | インフルエンザウイルスの増殖方法 |
| GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
| CA3016948A1 (en) * | 2006-09-11 | 2008-03-20 | Seqirus UK Limited | Making influenza virus vaccines without using eggs |
| KR101464783B1 (ko) | 2006-09-15 | 2014-11-26 | 메디뮨 엘엘씨 | 높은 역가로 바이러스 증식을 지원하는 ｍｄｃｋ 세포주 및 이를 이용한 생물반응기 공정 |
| ES2480491T3 (es) | 2006-12-06 | 2014-07-28 | Novartis Ag | Vacunas incluyendo antígeno de cuatro cepas de virus de la gripe |
| CA2690196A1 (en) * | 2007-06-18 | 2008-12-24 | Medimmune, Llc | Influenza b viruses having alterations in the hemaglutinin polypeptide |
| US9474798B2 (en) | 2007-06-18 | 2016-10-25 | Wisconsin Alumni Research Foundation | Influenza M2 protein mutant viruses as live influenza attenuated vaccines |
| EA201070066A1 (ru) * | 2007-06-27 | 2010-06-30 | Новартис Аг | Вакцины против гриппа с низким содержанием добавок |
| US20090042253A1 (en) * | 2007-08-09 | 2009-02-12 | Wyeth | Use of perfusion to enhance production of fed-batch cell culture in bioreactors |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| NZ586439A (en) | 2007-12-24 | 2012-10-26 | Novartis Ag | Method for peforming an immunodiffusion assay (SRID) for influenza hemagglutinin antigen based on desorbing the antigen from the aluminium adjuvant salt |
| US8506966B2 (en) | 2008-02-22 | 2013-08-13 | Novartis Ag | Adjuvanted influenza vaccines for pediatric use |
| EP2268309B1 (en) | 2008-03-18 | 2015-01-21 | Novartis AG | Improvements in preparation of influenza virus vaccine antigens |
| TW201012930A (en) * | 2008-06-16 | 2010-04-01 | Intervet Int Bv | Method of replicating viruses in suspension |
| CA2733356C (en) * | 2008-08-01 | 2016-06-07 | Gamma Vaccines Pty Limited | Influenza vaccines |
| CA2738024A1 (en) | 2008-09-24 | 2010-04-01 | Medimmune, Llc | Methods for purification of viruses |
| CN103952376A (zh) | 2008-09-24 | 2014-07-30 | 米迪缪尼有限公司 | 培养细胞、增殖和纯化病毒的方法 |
| WO2010079081A1 (en) | 2009-01-07 | 2010-07-15 | Glaxosmithkline Biologicals S.A. | Methods for recovering a virus or a viral antigen produced by cell culture |
| EP2393922A1 (en) | 2009-02-06 | 2011-12-14 | GlaxoSmithKline Biologicals S.A. | Purification of virus or viral antigens by density gradient ultracentrifugation |
| EA201500910A1 (ru) | 2009-02-10 | 2016-04-29 | Новартис Аг | Вакцины против гриппа со сниженным количеством сквалена |
| CA2752041A1 (en) | 2009-02-10 | 2010-08-19 | Novartis Ag | Influenza vaccines with increased amounts of h3 antigen |
| US20120093859A1 (en) | 2009-02-10 | 2012-04-19 | Novartis Ag | Influenza vaccine regimens for pandemic-associated strains |
| CA2763816A1 (en) | 2009-04-27 | 2010-11-04 | Novartis Ag | Adjuvanted vaccines for protecting against influenza |
| CN102803515A (zh) | 2009-05-08 | 2012-11-28 | 诺华有限公司 | 用于流感病毒检测的通用测试 |
| SI2401384T1 (sl) | 2009-05-21 | 2013-01-31 | Novartis Ag | Reverzna genetika z uporabo neendogenih pol i promotorjev |
| EP2435066B1 (en) | 2009-05-29 | 2013-11-20 | Novartis AG | Assays for influenza virus hemagglutinins |
| JP2013500712A (ja) | 2009-07-31 | 2013-01-10 | ノバルティス アーゲー | 逆遺伝学系 |
| WO2011030218A1 (en) | 2009-09-10 | 2011-03-17 | Novartis Ag | Combination vaccines against respiratory tract diseases |
| EP2491117B2 (en) | 2009-10-20 | 2017-06-28 | Novartis AG | Improved reverse genetics methods for virus rescue |
| JP2013507990A (ja) | 2009-10-26 | 2013-03-07 | ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション | ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス |
| DE102009056884B4 (de) | 2009-12-03 | 2021-03-18 | Novartis Ag | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
| US20130189311A1 (en) | 2009-12-03 | 2013-07-25 | Novartis Ag | Arranging interaction and back pressure chambers for microfluidization |
| CA2780425C (en) | 2009-12-03 | 2014-02-04 | Novartis Ag | Hydrophilic filtration during manufacture of vaccine adjuvants |
| MX344381B (es) | 2009-12-03 | 2016-12-14 | Novartis Ag | Circulacion de componentes durante la homogenizacion de emulsiones. |
| DE102009056871A1 (de) | 2009-12-03 | 2011-06-22 | Novartis AG, 4056 | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
| DE102009056883B4 (de) | 2009-12-03 | 2012-08-16 | Novartis Ag | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
| EP2531592A1 (en) | 2010-02-04 | 2012-12-12 | Vivalis | Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells |
| US9494571B2 (en) | 2010-03-08 | 2016-11-15 | Novartis Ag | Methods of testing for intracellular pathogens |
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| JP6200805B2 (ja) | 2010-05-03 | 2017-09-20 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 新規な方法 |
| JP6072677B2 (ja) | 2010-05-06 | 2017-02-01 | ノバルティス アーゲー | 微生物の不活化のための有機ペルオキシド化合物 |
| EA027142B1 (ru) | 2010-05-12 | 2017-06-30 | Новартис Аг | Улучшенные способы получения сквалена |
| CN103025350A (zh) | 2010-05-21 | 2013-04-03 | 诺华有限公司 | 流感病毒的重配方法 |
| HUE051711T2 (hu) | 2010-06-01 | 2021-03-29 | Seqirus Uk Ltd | Influenzavakcina antigénjeinek koncentrálása liofilizálás nélkül |
| BR112012030616A2 (pt) | 2010-06-01 | 2017-03-01 | Novartis Ag | concentração de antígenos de vacina com liofilização. |
| JP5928843B2 (ja) * | 2010-08-16 | 2016-06-01 | ツェヴェック ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | インフルエンザウイルスを製造するための永久ヒト羊膜細胞株 |
| US9051361B2 (en) | 2010-08-17 | 2015-06-09 | National Health Research Institutes | Immunogenic compositions and uses thereof |
| ES2531577T3 (es) | 2010-08-20 | 2015-03-17 | Novartis Ag | Conjuntos de agujas para la administración de vacuna soluble contra la gripe |
| WO2012032482A1 (en) | 2010-09-07 | 2012-03-15 | Novartis Ag | Generic assays for detection of mammalian reovirus |
| EP2667891B1 (en) | 2011-01-27 | 2021-10-06 | Gamma Vaccines Pty Limited | Combination vaccines |
| AU2012221740B2 (en) | 2011-02-25 | 2016-11-17 | Novartis Ag | Exogenous internal positive control |
| JP2014527799A (ja) | 2011-08-26 | 2014-10-23 | ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション | 変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス |
| GB201216121D0 (en) | 2012-09-10 | 2012-10-24 | Novartis Ag | Sample quantification by disc centrifugation |
| EP2768528A1 (en) | 2011-10-20 | 2014-08-27 | Novartis AG | Adjuvanted influenza b virus vaccines for pediatric priming |
| ES2564138T3 (es) | 2011-12-12 | 2016-03-18 | Novartis Ag | Ensayo para Hemaglutinina del virus de la influenza |
| AU2014203051C1 (en) * | 2012-03-02 | 2016-09-01 | Seqirus UK Limited | Influenza Virus Reassortment |
| EP2820126B1 (en) | 2012-03-02 | 2017-05-17 | Seqirus UK Limited | Influenza virus reassortment |
| CN104159608A (zh) | 2012-03-06 | 2014-11-19 | 克鲁塞尔荷兰公司 | 针对流感的改善的疫苗接种 |
| JP6152535B2 (ja) * | 2012-04-16 | 2017-06-28 | 公益財団法人ヒューマンサイエンス振興財団 | 細胞培養組成物及びインフルエンザウイルスの生産方法 |
| AU2013270793A1 (en) | 2012-06-04 | 2014-12-11 | Novartis Ag | Improved safety testing |
| GB201218195D0 (en) | 2012-10-10 | 2012-11-21 | Istituto Zooprofilattico Sperimentale Delle Venezie | Composition |
| CA2893429A1 (en) | 2012-12-03 | 2014-06-12 | Synthetic Genomics Vaccines, Inc. | Influenza virus reassortment |
| EP2968512A2 (en) | 2013-03-13 | 2016-01-20 | Novartis AG | Influenza b virus reassortment |
| AU2014264501A1 (en) | 2013-05-10 | 2015-12-10 | Novartis Ag | Avoiding narcolepsy risk in influenza vaccines |
| DE202013005100U1 (de) | 2013-06-05 | 2013-08-26 | Novartis Ag | Influenza Virus Reassortierung |
| DE202013005130U1 (de) | 2013-06-05 | 2013-09-10 | Novartis Ag | Influenza Virus Reassortierung |
| HK1222882A1 (zh) | 2013-06-06 | 2017-07-14 | Novartis Ag | 流感病毒重配 |
| KR101370512B1 (ko) * | 2013-06-07 | 2014-03-06 | 재단법인 목암생명공학연구소 | 무단백 배지에서 부유 배양되는 mdck 유래 세포주 및 상기 세포주를 이용하여 바이러스를 증식시키는 방법 |
| EP3022296B1 (en) | 2013-07-15 | 2022-12-28 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs |
| CA2920934C (en) | 2013-08-30 | 2022-12-06 | Glaxosmithkline Biologicals S.A. | Large scale production of viruses in cell culture |
| KR20160068972A (ko) | 2013-11-15 | 2016-06-15 | 노파르티스 아게 | 잔여 세포 배양 불순물의 제거 |
| TW202204596A (zh) | 2014-06-06 | 2022-02-01 | 美商健臻公司 | 灌注培養方法及其用途 |
| TWI776235B (zh) * | 2014-06-09 | 2022-09-01 | 美商健臻公司 | 種子罐培養法(seed train processes)及其用途 |
| WO2015196150A2 (en) | 2014-06-20 | 2015-12-23 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| AU2015252119A1 (en) | 2014-11-07 | 2016-05-26 | Takeda Vaccines, Inc. | Hand, foot, and mouth vaccines and methods of manufacture and use thereof |
| AR102547A1 (es) | 2014-11-07 | 2017-03-08 | Takeda Vaccines Inc | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso |
| WO2016087479A1 (en) | 2014-12-02 | 2016-06-09 | Novartis Ag | Manufacture of surfactant-containing compositions |
| US10633422B2 (en) | 2015-06-01 | 2020-04-28 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA |
| EP3313439A2 (en) | 2015-06-26 | 2018-05-02 | Seqirus UK Limited | Antigenically matched influenza vaccines |
| US9890363B2 (en) | 2015-07-06 | 2018-02-13 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
| KR102576962B1 (ko) | 2015-07-07 | 2023-09-11 | 세퀴러스 유케이 리미티드 | 인플루엔자 효능 검정 |
| WO2017072744A1 (en) | 2015-10-30 | 2017-05-04 | National Institute Of Infectious Diseases And Vaccinology, National Health Research Institutes | Mdck suspension cell lines in serum-free, chemically-defined media for vaccine production |
| JP2019510481A (ja) | 2016-02-19 | 2019-04-18 | ウィスコンシン アルムニ リサーチ ファンデイション | ワクチン開発のための改善されたｂ型インフルエンザウイルス複製 |
| US20190078056A1 (en) | 2016-03-29 | 2019-03-14 | The Research Foundation For Microbial Diseases Of Osaka University | Method for culturing mdck cells |
| JP2017038622A (ja) * | 2016-11-21 | 2017-02-23 | ウィスコンシン アルムニ リサーチ ファンデイション | Ｈ３型ウマａ型インフルエンザウイルス |
| EP3700562A1 (en) | 2017-10-25 | 2020-09-02 | Wisconsin Alumni Research Foundation (WARF) | Recombinant influenza viruses with stabilized ha for replication in eggs |
| CA3081581A1 (en) | 2017-11-03 | 2019-05-09 | Takeda Vaccines, Inc. | Method for inactivating zika virus and for determining the completeness of inactivation |
| JP7783047B2 (ja) | 2018-08-07 | 2025-12-09 | ウィスコンシン アルムニ リサーチ ファンデイション | 組換えの生物学的に封じ込められたフィロウイルスワクチン |
| EP3840780A1 (en) | 2018-08-20 | 2021-06-30 | Wisconsin Alumni Research Foundation | Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (ha) protein |
| EP3914295A2 (en) | 2019-01-23 | 2021-12-01 | Yoshihiro Kawaoka | Mutations that confer genetic stability to additional genes in influenza viruses |
| US11851648B2 (en) | 2019-02-08 | 2023-12-26 | Wisconsin Alumni Research Foundation (Warf) | Humanized cell line |
| WO2020223699A1 (en) | 2019-05-01 | 2020-11-05 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza virus replication for vaccine development |
| CA3137652A1 (en) | 2019-05-08 | 2020-11-12 | Takeda Vaccines, Inc. | Inactivated virus compositions and zika vaccine formulations |
| WO2021041624A2 (en) | 2019-08-27 | 2021-03-04 | Yoshihiro Kawaoka | Recombinant influenza viruses with stabilized ha for replication in eggs |
| US20230000971A1 (en) | 2019-11-18 | 2023-01-05 | Seqirus Pty Ltd. | Method for producing reassortant influenza viruses |
| JP2023511444A (ja) | 2020-01-24 | 2023-03-17 | ウィスコンシン アルムニ リサーチ ファンデイション | 安定化されたｎａを有する組換えインフルエンザウイルス |
| US12290562B2 (en) | 2020-03-25 | 2025-05-06 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
| WO2022003560A1 (en) | 2020-06-30 | 2022-01-06 | Seqirus UK Limited | Cold filtration of oil-in-water emulsion adjuvants |
| EP4476329A1 (en) | 2022-02-09 | 2024-12-18 | Takeda Vaccines, Inc. | Zika vaccines and immunogenic compositions, and methods of using the same |
| CN116376810A (zh) * | 2023-04-26 | 2023-07-04 | 上海奥浦迈生物科技股份有限公司 | 一种mdck细胞无血清贴壁培养驯化的方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3616203A (en) * | 1969-12-11 | 1971-10-26 | Norden Lab Inc | Virus culture and method |
| US4500513A (en) * | 1979-05-15 | 1985-02-19 | Miles Laboratories, Inc. | Influenza vaccine production in liquid cell culture |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1278075B (de) * | 1964-06-22 | 1968-09-19 | Norden Lab Inc | Verwendung von Gewebekulturen zur Zuechtung von Viren fuer die Gewinnung von Impfstoffen |
| US4064232A (en) | 1974-01-14 | 1977-12-20 | Sandoz Ltd. | Process for isolating the immunogenic components of influenza viruses |
| USRE33164E (en) * | 1979-05-15 | 1990-02-13 | Mobay Corporation | Influenza vaccine production in liquid cell culture |
| CA1122527A (en) | 1979-05-15 | 1982-04-27 | Karen K. Brown | Influenza vaccine production in liquid cell culture |
| US5013663A (en) * | 1983-06-15 | 1991-05-07 | American Home Products Corporation | Canine corona virus vaccine |
| US4783411A (en) | 1984-10-22 | 1988-11-08 | Janis Gabliks | Influenza-A virus vaccine from fish cell cultures |
| EP0389925B1 (en) | 1989-03-29 | 1995-12-27 | The Research Foundation Of State University Of New York | A method for purifying an outer membrane protein of Haemophilus influenzae |
| JP2827298B2 (ja) * | 1989-07-10 | 1998-11-25 | 三菱化学株式会社 | 細胞培養担体 |
| AT393277B (de) | 1990-01-04 | 1991-09-25 | Immuno Ag | Verfahren zur herstellung von fruehsommer- meningoenzephalitis-virus (fsme-virus)-antigen |
| JPH0420284A (ja) * | 1990-05-12 | 1992-01-23 | Mitsubishi Kasei Corp | 細胞培養用マイクロキャリア |
| JPH05207873A (ja) * | 1992-01-27 | 1993-08-20 | Mitsubishi Kasei Corp | 付着性動物細胞の培養方法 |
| US5762939A (en) * | 1993-09-13 | 1998-06-09 | Mg-Pmc, Llc | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus |
| DK0791055T3 (da) | 1994-11-10 | 2012-04-16 | Baxter Healthcare Sa | Fremgangsmåde til fremstilling af biologiske produkter i proteinfri kultur |
| US5756341A (en) * | 1994-11-10 | 1998-05-26 | Immuno Ag | Method for controlling the infectivity of viruses |
| US5753489A (en) * | 1994-11-10 | 1998-05-19 | Immuno Ag | Method for producing viruses and vaccines in serum-free culture |
| WO1996015232A1 (en) | 1994-11-16 | 1996-05-23 | St. Jude Children's Research Hospital | Novel replication process |
| US5646033A (en) * | 1994-11-30 | 1997-07-08 | Dyncorp | African green monkey kidney cell lines useful for maintaining viruses and for preparation of viral vaccines |
| CN1285608C (zh) | 1995-09-22 | 2006-11-22 | 康诺特实验室有限公司 | 副流感病毒糖蛋白和疫苗 |
| DE19612966B4 (de) * | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| DE19612967A1 (de) | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
| US6514502B1 (en) * | 1999-01-26 | 2003-02-04 | Schering-Plough Veterinary Corporation | Propagation of bovine cononavirus in chinese hamster ovary cells |
-
1996
- 1996-04-01 DE DE19612966A patent/DE19612966B4/de not_active Expired - Fee Related
-
1997
- 1997-04-01 PT PT97915627T patent/PT904351E/pt unknown
- 1997-04-01 AT AT97915627T patent/ATE482267T1/de active
- 1997-04-01 EP EP97915627A patent/EP0904351B1/en not_active Expired - Lifetime
- 1997-04-01 ES ES97915627T patent/ES2352638T3/es not_active Expired - Lifetime
- 1997-04-01 WO PCT/IB1997/000403 patent/WO1997037000A1/en not_active Ceased
- 1997-04-01 JP JP53508997A patent/JP4243349B2/ja not_active Expired - Fee Related
- 1997-04-01 DK DK97915627.0T patent/DK0904351T3/da active
- 1997-04-01 US US09/155,581 patent/US6455298B1/en not_active Expired - Lifetime
- 1997-04-01 EP EP10075278A patent/EP2275535A1/en not_active Withdrawn
- 1997-04-01 DE DE69740002T patent/DE69740002D1/de not_active Expired - Lifetime
-
2002
- 2002-07-12 US US10/194,784 patent/US6656720B2/en not_active Expired - Lifetime
-
2004
- 2004-08-10 JP JP2004233905A patent/JP2004331673A/ja not_active Withdrawn
-
2005
- 2005-02-15 US US11/057,370 patent/US20050202553A1/en not_active Abandoned
- 2005-04-04 JP JP2005108075A patent/JP2005211080A/ja not_active Withdrawn
-
2006
- 2006-05-26 JP JP2006147486A patent/JP2006230415A/ja not_active Withdrawn
-
2008
- 2008-06-26 US US12/146,689 patent/US20080274141A1/en not_active Abandoned
- 2008-11-07 JP JP2008287206A patent/JP2009034115A/ja not_active Withdrawn
-
2011
- 2011-09-02 JP JP2011192118A patent/JP2012005502A/ja not_active Withdrawn
- 2011-10-12 JP JP2011224914A patent/JP2012016358A/ja not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3616203A (en) * | 1969-12-11 | 1971-10-26 | Norden Lab Inc | Virus culture and method |
| US4500513A (en) * | 1979-05-15 | 1985-02-19 | Miles Laboratories, Inc. | Influenza vaccine production in liquid cell culture |
Non-Patent Citations (4)
| Title |
|---|
| Advances in "abstract" 1-32 CAPLUS experimental S.143, S.145 * |
| Advances in "abstract" 1-32 CAPLUS experimental S.143, S.145 Medicine and Biology Vol.397, 1996, S.141-151 Principles and techniques of practical biochemistry, 4. Aufl., ed, K. Wilson J. and J.M. Walker Cambridge University Press S. 21. ATCC Katalog "ATCC NummerCC2-34" |
| Medicine and Biology Vol.397, 1996, S.141-151 * |
| Principles and techniques of practical biochemistry, 4. Aufl., ed, K. Wilson J. and J.M. Walker Cambridge University Press S. 21. ATCC Katalog "ATCC NummerCC2-34" * |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2352638T3 (es) | 2011-02-22 |
| EP2275535A1 (en) | 2011-01-19 |
| US20080274141A1 (en) | 2008-11-06 |
| DE69740002D1 (de) | 2010-11-04 |
| US20030073223A1 (en) | 2003-04-17 |
| JP2004331673A (ja) | 2004-11-25 |
| JP2012005502A (ja) | 2012-01-12 |
| EP0904351A1 (en) | 1999-03-31 |
| JP2000507448A (ja) | 2000-06-20 |
| JP2006230415A (ja) | 2006-09-07 |
| HK1019233A1 (en) | 2000-01-28 |
| DK0904351T3 (da) | 2010-11-01 |
| JP4243349B2 (ja) | 2009-03-25 |
| WO1997037000A1 (en) | 1997-10-09 |
| US20050202553A1 (en) | 2005-09-15 |
| JP2009034115A (ja) | 2009-02-19 |
| ATE482267T1 (de) | 2010-10-15 |
| US6656720B2 (en) | 2003-12-02 |
| JP2012016358A (ja) | 2012-01-26 |
| EP0904351B1 (en) | 2010-09-22 |
| PT904351E (pt) | 2010-12-28 |
| DE19612966A1 (de) | 1997-10-02 |
| US6455298B1 (en) | 2002-09-24 |
| JP2005211080A (ja) | 2005-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE19612966B4 (de) | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren | |
| DE10144906B4 (de) | Verfahren zur großtechnischen Herstellung von Impfstoffen | |
| EP1427817B1 (de) | Vermehrung von viren in zellkultur | |
| DE69732407T3 (de) | Verfahren für die Replikation von Influenza in Zellkultur und die bei diesem Verfahren hergestellten Influenza-Viren | |
| DE60222296T2 (de) | Impfstoff von umhüllten viren und verfahren zu seiner herstellung | |
| CA1144860A (en) | Compositions of matter | |
| DE19655440B4 (de) | Verfahren zur Herstellung eines Influenzaimpfstoffs | |
| CA2250714C (en) | Animal cells and processes for the replication of influenza viruses | |
| HK1152546A (en) | Animal cells and processes for the replication of influenza viruses | |
| HK1019233B (en) | Animal cells and processes for the replication of influenza viruses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8127 | New person/name/address of the applicant |
Owner name: CHIRON BEHRING GMBH & CO., 35039 MARBURG, DE |
|
| 8110 | Request for examination paragraph 44 | ||
| 8127 | New person/name/address of the applicant |
Owner name: NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO. K, DE |
|
| 8172 | Supplementary division/partition in: |
Ref document number: 19655438 Country of ref document: DE Kind code of ref document: P |
|
| Q171 | Divided out to: |
Ref document number: 19655438 Country of ref document: DE Kind code of ref document: P |
|
| AH | Division in |
Ref document number: 19655438 Country of ref document: DE Kind code of ref document: P |
|
| 8364 | No opposition during term of opposition | ||
| R082 | Change of representative |
Representative=s name: UEXKUELL & STOLBERG, 22607 HAMBURG, DE Representative=s name: UEXKUELL & STOLBERG, DE |
|
| R079 | Amendment of ipc main class |
Free format text: PREVIOUS MAIN CLASS: C12N0005060000 Ipc: C12N0005070000 |
|
| R079 | Amendment of ipc main class |
Free format text: PREVIOUS MAIN CLASS: C12N0005060000 Ipc: C12N0005070000 Effective date: 20120613 |
|
| R081 | Change of applicant/patentee |
Owner name: NOVARTIS VACCINES AND DIAGNOSTICS GMBH, DE Free format text: FORMER OWNER: NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO. KG, 35041 MARBURG, DE Effective date: 20111209 |
|
| R082 | Change of representative |
Representative=s name: UEXKUELL & STOLBERG, DE Effective date: 20111209 Representative=s name: UEXKUELL & STOLBERG PARTNERSCHAFT VON PATENT- , DE Effective date: 20111209 |
|
| R119 | Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee |